Assessment of Effectiveness and Impact of Universal Prophylaxis With Nirsevimab for Prevention of Hospitalizations Due to Respiratory Syncytial Virus in Infants. The NIRSE-GAL Study Protocol

• 2024

  Log in to bookmark this resource.

  Log in
• Narmeen Mallah; Sonia Ares-Gómez; Jacobo Pardo-Seco; Alberto Malvar-Pintos; María-Isolina Santiago-Pérez; Olaia Pérez-Martínez
PMID: 38738683DOI: https://dx.doi.org/10.1080/21645515.2024.2348135

---

Access Resources

• Journal ArticleEN
• Ask aRCie About This Resource

About

The NIRSE-GAL study in Galicia, Spain, aims to assess the effectiveness of nirsevimab in preventing hospitalizations due to Respiratory Syncytial Virus (RSV) in infants. It describes a three-year plan starting from 2023, focusing on infants born during the RSV season and those at high risk. The study will monitor RSV cases and evaluate nirsevimab's impact on healthcare use and respiratory conditions like wheezing and asthma. Data will be collected through digital health systems, with findings shared via publications and conferences to inform public health decisions about RSV prevention strategies.

---

Tags

Focus Area: Infectious Disease

Audiences: Nurses; Physicians; Public Health Professionals

Emergency Management Stage: Preparedness (Prevention / Protection)

Collection: Nirsevimab Library

Keywords: Child; Epidemiology; Hospitalization; Infant; Infant, Newborn; Respiratory Syncytial Virus Infections; Respiratory Syncytial Viruses; Respiratory Tract Infections; Spain; Immunization Programs; Palivizumab; Antibodies, Monoclonal, Humanized; Public Health Surveillance

Institutions: Instituto de Investigación Sanitaria; World Health Organization (WHO); University of Santiago de Compostela; Instituto de Salud Carlos III

---

More like this

Assessment of Effectiveness and Impact of Universal Prophylaxis With Nirsevimab for Prevention of Hospitalizations Due to Respiratory Syncytial Virus in Infants. The NIRSE-GAL Study Protocol 2024 · Instituto de Investigación Sanitaria, World Health Organization (WHO), University of Santiago de Compostela, Instituto de Salud Carlos III Potential Effects on Elderly People From Nirsevimab Use in Infants 2024 · World Health Organization (WHO), Instituto de Estudios de Ciencias de la Salud de Castilla y León, ICSCYL, Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFECC), University of Valladolid The Respiratory Syncytial Virus Vaccine and Monoclonal Antibody Landscape: The Road to Global Access 2024 · University Medical Center Utrecht, Yenepoya University, University of Edinburgh, National Institutes of Health (NIH), London School of Hygiene and Tropical Medicine

---

The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

---